5198-86-7

Basic information

• Product Name: 2-BROMO-4-HYDROXYMETHYLTHIAZOLE
• Synonyms: 2-BROMOTHIAZOLE-4-METHANOL;(2-BROMO-1,3-THIAZOLE-4-YL)METHANOL;2-BROMO-4-HYDROXYMETHYLTHIAZOLE;2-Bromo-4-(hydroxymethyl)-1,3-thiazole;2-Bromo-4-(hydroxymethyl)-1,3-thiazole 97%;(2-bromothiazol-4-yl)methanol;(2-bromo-1,3-thiazol-4-yl)methanol;(2-bromo-1,3-thiazol-4-yl)methanol(SALTDATA: HCl)
• CAS NO: 5198-86-7
• Molecular Formula: C₄H₄BrNOS
• Molecular Weight: 194.05
• Product Categories: blocks;Bromides;Thiazoles;API intermediates
• Mol File: 5198-86-7.mol
• Article Data: 23

Chemical Properties

• Boiling Point: 288.3 °C at 760 mmHg
• Flash Point: 128.1 °C
• Appearance: /
• Density: 1.899 g/cm₃
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.642
• Storage Temp.: Keep Cold
• PKA: 12.82±0.10(Predicted)
• CAS DataBase Reference: 2-BROMO-4-HYDROXYMETHYLTHIAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-4-HYDROXYMETHYLTHIAZOLE(5198-86-7)
• EPA Substance Registry System: 2-BROMO-4-HYDROXYMETHYLTHIAZOLE(5198-86-7)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• Hazardous Substances Data: 5198-86-7(Hazardous Substances Data)

Usage

General Description

2-Bromo-4-hydroxymethylthiazole is a chemical compound that contains a thiazole ring with a bromine atom and a hydroxymethyl group attached. It is commonly used as a building block in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds due to its reactivity and versatility. 2-BROMO-4-HYDROXYMETHYLTHIAZOLE is also used as a preservative and antimicrobial agent in various industrial applications, including in the production of food, beverages, and personal care products. The bromine atom and hydroxymethyl group in 2-Bromo-4-hydroxymethylthiazole give it unique properties that make it a valuable tool in the field of organic chemistry and chemical synthesis.

InChI:InChI=1/C4H4BrNOS/c5-4-6-3(1-7)2-8-4/h2,7H,1H2

Upstream product

• 5198-80-1 2-bromothiazole-4-carbaldehyde 
• 170235-26-4 2-bromo-thiazole-4-carboxylic acid methyl ester 
• 100367-77-9 ethyl 2-bromothiazole-4-carboxylate 

Downstream Products

• 936691-31-5 2-bromo-4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-1,3-thiazole 
• 263169-23-9 2-bromo-4-((tert-butyldiphenylsilyloxy)methyl)thiazole 
• 1236031-60-9 (+/-)-tert-butyl 4-(4-(hydroxymethyl)thiazol-2-yl)-1-(4-(trifluoromethyl)phenyl)but-3-yn-2-ylcarbamate 
• 5198-80-1 2-bromothiazole-4-carbaldehyde 
• 180597-85-7 2-bromo-4-(bromomethyl)-1,3-thiazole 

Relevant articles and documents

Synthesis and evaluation of novel and potent protease activated receptor 4 (PAR4) antagonists based on a quinazolin-4(3H)-one scaffold

Protease activated receptor 4 (PAR4) is an important target in antiplatelet therapy to reduce the risk of heart attack and thrombotic complications in stroke. PAR4 antagonists can prevent harmful and stable thrombus growth, while retaining initial thrombus formation, by acting on the late diffusion stage of platelet aggregation, and may provide a safer alternative to other antiplatelet agents. To date, only two PAR4 antagonists, BMS-986120 and BMS-986141 have entered clinical trials for thrombosis. Thus, the development of a potent and selective PAR4 antagonist with a novel chemotype is highly desirable. In this study, we explored the activity of quinazolin-4(3H)-one-based PAR4 antagonists, beginning with their IDT analogues. By repeated structural optimisation, we developed a series of highly selective PAR4 antagonists with nanomolar potency on human platelets. Of these, 13 and 30g, with an 8-benzo[d]thiazol-2-yl-substituted quinazolin-4(3H)-one structure, showed optimal activity (h. PAR4-AP PRP IC50 = 19.6 nM and 6.59 nM, respectively) on human platelets. Furthermore, 13 and 30g showed excellent selectivity for PAR4 versus PAR1 and other receptors (IC50s > 10 μM) on human platelets. And 13 and 30g were lack of cross-reactivity for PAR1 or PAR2 (PAR1 AP FLIPR IC50 > 3162 nM, PAR2 AP FLIPR IC50 > 1000 nM) in the calcium mobilization assays. Metabolic stability assays and cytotoxicity tests of 13 and 30g indicated that these compounds could sever as promising drug candidates for the development of novel PAR4 antagonists. In summary, the quinazolin-4(3H)-one-based analogues are the first reported chemotypes with excellent activity and selectivity against PAR4, and, in the current study, we expanded the structural diversity of PAR4 antagonists. The two compounds, 13 and 30g, found in our study could be promising starting points with great potential for further research in antiplatelet therapy.

NLRP MODULATORS

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein, useful to treat connected to the modulation of NRLP3.

METHODS OF TREATING CANCER

The present disclosure relates to methods of treating cancer in a patient using a combination of an inhibitor of an immune checkpoint protein and an indole compound or its phosphate derivative.